Advertisement

Interleukin-6: A comprehensive review

  • Martin Lotz
Part of the Cancer Treatment and Research book series (CTAR, volume 80)

Abstract

Interleukin-6 (IL-6) is a cytokine which plays a prominent role in the coordinated systemic host defense response to injury. IL-6 regulates immune and inflammatory responses, hepatic acute-phase protein synthesis, hemato-poiesis, and bone metabolism. The structure of IL-6 gene and protein, and biological activities of the cytokine, are well characterized. The composition of the IL-6 receptor has been identified, and there has been substantial recent progress in the analysis of IL-6-activated signal transduction mechanisms. IL-6 expression in different disease states has been demonstrated; IL-6 may be involved as a mediator in certain aspects in the pathogenesis of infection, autoimmunity, and malignancy.

Keywords

Multiple Myeloma Epithelial Ovarian Cancer Leukemia Inhibitory Factor Isolate Limb Perfusion Human Myeloma Cell Line 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kishimoto T. The biology of interleukin-6. Blood 74:1–10, 1989.PubMedGoogle Scholar
  2. 2.
    Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T, Kashiwamura S, Nakajima K, Koyama K, Iwamatsu A.Complementary DNA for a novel human inter-leukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324:73–76, 1986.PubMedCrossRefGoogle Scholar
  3. 3.
    Sehgal PB, Zilberstein A, Ruggieri RM, May LT, Ferguson-Smith A, Slate DL, Revel M, Ruddle FH. Human chromosome 7 carries the beta 2 interferon gene. Proc Natl Acad Sci USA 83:5219–5222, 1986.PubMedCrossRefGoogle Scholar
  4. 4.
    Yasukawa K, Hirano T, Watanabe Y, Muratani K, Matsuda T, Nakai S, Kishimoto T. Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6) gene. EMBO J 6:2939–2945, 1987.PubMedGoogle Scholar
  5. 5.
    May LT, Ghrayeb J, Santhanam U, Tatter SB, Sthoeger Z, Helfgott DC, Chiorazzi N, Grieninger G, Sehgal PB. Synthesis and secretion of multiple forms of beta 2–interferon/ B-cell differentiation factor 2/hepatocyte-stimutating factor by human fibroblasts and monocytes. J Biol Chem 263:7760–7766, 1988.PubMedGoogle Scholar
  6. 6.
    Santhanam UJ, Sehgal PB, May LT. Post-translational modifications of human interleukin-6. Arch Biochem Biophys 274:161–170, 1989.PubMedCrossRefGoogle Scholar
  7. 7.
    May LT, Santhanam U, Tatter SB, Bhardwaj N, Ghrayeb J, Sehgal PB. Phosphorcylation of secreted forms of human beta 2-interferon/hepatocyte stimulating factor/interleukin-6. Biochem Biophys Res Commun 152:1144–1150, 1988.PubMedCrossRefGoogle Scholar
  8. 8.
    May LT, Viguet H, Kenney JS, Ida N, Allison AC, Sehgal PB. High levels of “com-plexed” interleukin-6 in human blood. J Biol Chem 267:19698–19704, 1992.PubMedGoogle Scholar
  9. 9.
    Hamid Q, Barkans J, Meng Q, Ying S, Abrams JS, Kay AB, Moqbel R. Human eosinophils synthesize and secrete interleukin-6, in vitro. Blood 80:1496–1501, 1992.PubMedGoogle Scholar
  10. 10.
    Van Snick J. Interleukin-6. Ann Rev Immunol 8:253–278, 1990.Google Scholar
  11. 11.
    Lotz M, Vaughan JH, Carson DA. Effect of neuropeptides on production of inflammatory cytokines by human monocytes. Science 241:1218–1221, 1988.PubMedCrossRefGoogle Scholar
  12. 12.
    Brach MA, de Vos S, Arnold C, Gruss HJ, Mertelsmann R, Herrmann F. Leukotriene B4 transcriptionally activates interleukin-6 expression involving NK-chi B and NF-IL6. Eur J Immunol 22:2705–2711, 1992.PubMedCrossRefGoogle Scholar
  13. 13.
    Gruss HJ, Brach MA, Herrmann F. Involvement of nuclear factor-kappa B in induction of the interleukin-6 gene by leukemia inhibitory factor. Blood 80:2563–2570, 1992.PubMedGoogle Scholar
  14. 14.
    Sawada M, Suzumura A, Kondo N, Marunouchi T. Induction of cytokines in glial cells by trans activator of human T-cell lymphotropic virus type I. FEBS Lett 313:47–50, 1992.PubMedCrossRefGoogle Scholar
  15. 15.
    Villiger PM, Cronin MT, Amenomori T, Wachsman W, Lotz M. IL-6 production by human T lymphocytes. Expression in HTLV-1-infected but not in normal T cells IL-6 production by human T lymphocytes. Expression in HTLV-1-infected but not in normal T cells. J Immunol 146:550–559, 1991.PubMedGoogle Scholar
  16. 16.
    Amano Y, Lee SW, Allison AC. Inhibition by glucocorticoids of the formation of inter-leukin-1 alpha, interleukin-1 beta, and interleukin-6: Mediation by decreased mRNA stability. Mol Pharmacol, 43:176–182, 1993.PubMedGoogle Scholar
  17. 17.
    Gross V, Villiger P, Zhang B, Lotz M. Retinoic acid inhibits IL-1 induced cytokine synthesis in human monocytes. J Leukoc Biol 54:124–132, 1993.Google Scholar
  18. 18.
    de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, deVries JE. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J Exp Med 174:1209–1220, 1991.PubMedCrossRefGoogle Scholar
  19. 19.
    Gibbons R, Martinez O, Math M, Heinzel F, Bernstein M, Warren R. Recombinant IL-4 inhibits IL-6 synthesis by adherent peripheral blood cells in vitro. Lymphokine Res 9:283–293, 1990.PubMedGoogle Scholar
  20. 20.
    Gross V, Zhang B, Geng Y, Villiger P, Lotz M. Regulation of IL-6 expression. Evidence for a tissue-specific role of protein kinase C. J Clin Immunol 15:310–320, 1993.CrossRefGoogle Scholar
  21. 21.
    Geng Y, Zhang B, Lotz M. LPS induction of cytokines in human blood monocytes is protein tyrosine kinase dependent. J Immunol 151:6692–6700, 1993.PubMedGoogle Scholar
  22. 22.
    Sehgal PB. Interleukin-6: Molecular pathophysiology. J Invest Dermatol 94:2S–6S, 1990.Google Scholar
  23. 23.
    Akira S, Isshiki H, Nakajima T, Kinoshita S, Nishio Y, Natsuka S, Kishimoto T. Regulation of expression of the interleukin 6 gene: Structure and function of the transcription factor NF-IL6. Ciba Found Symp 167:47–62, 1992.PubMedGoogle Scholar
  24. 24.
    Libermann TA, Baltimore D. Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol 10:2327–2334, 1990.PubMedGoogle Scholar
  25. 25.
    Shimizu H, Mitomo K, Watanabe T, Okamoto S, Yamamoto K. Involvement of a NF-kappa B-like transcription factor in the activation of the interleukin-6 gene by inflammatory lymphokines. Mol Cell Biol 10:561–568, 1990.PubMedGoogle Scholar
  26. 26.
    Matsusaka T, Fujikawa K, Nishio Y, Mukaida N, Matsushima K, Kishimoto T, Akira S. Transcription factors NF-IL6 and NF-kappa B synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc Natl Acad Sci USA 90: 10193–10197, 1993.PubMedCrossRefGoogle Scholar
  27. 27.
    Yamashita I, Katamine S, Moriuchi R, Nakamura Y, Miyamoto T, Eguchi K, Nagataki S. Transactivation of the human interleukin-6 gene by human T-lymphotropic virus type 1 Tax protein. Blood 84:1573–1578, 1994.PubMedGoogle Scholar
  28. 28.
    Ray A, LaForge KS, Sehgal PB. On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: Enhancer, TATA box, and RNA start site (Inr motif) occlusion. Mol Cell Biol 10:5736–5746, 1990.PubMedGoogle Scholar
  29. 29.
    Muraguchi A, Hirano T, Tang B, Matsuda T, Horii Y, Nakajima K, Kishimoto T. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med 167:332–344, 1988.PubMedCrossRefGoogle Scholar
  30. 30.
    Takatsuki F, Okano A, Suzuki C, Chieda R, Takahara Y, Hirano T, Kishimoto T, Hamuro J, Akiyama Y. Human recombinant IL-6/B cell stimulatory factor 2 augments murine antigen-specific antibody responses in vitro and in vivo. J Immunol 141:3072–3077, 1988.PubMedGoogle Scholar
  31. 31.
    Beagley KW, Eldridge JH, Lee F, Kiyono H, Everson MP, Koopman WJ, Hirano T, Kishimoto T, McGhee JR, Interleukins and IgA synthesis: Human and murine interleukin 6 induce high rate IgA secretion in IgA-committed B cells. J Exp Med 169:2133–2148, 1989.PubMedCrossRefGoogle Scholar
  32. 32.
    Lotz M, Jirik F, Kabouridis P, Tsoukas C, Hirano T, Kishimoto T, Carson DA, B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes. J Exp Med 167:1253–1258, 1988.PubMedCrossRefGoogle Scholar
  33. 33.
    Garman RD, Jacobs KA, Clark SC, Raulet DH. B-cell-stimulatory factor 2 (beta 2 interferon) functions as a second signal for interleukin 2 production by mature murine T cells. Proc Natl Acad Sci USA 84:7629–7633, 1987.PubMedCrossRefGoogle Scholar
  34. 34.
    Okada M, Kitahara M, Kishimoto S, Matsuda T, Hirano T, Kishimoto T. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol 141:1543–1549, 1988.PubMedGoogle Scholar
  35. 35.
    Houssiau F, Van Snick J. IL6 and the T-cell response. Res Immunol 143:740–743, 1992.PubMedCrossRefGoogle Scholar
  36. 36.
    Quentmeier H, Klaucke J, Muhlradt PF, Drexler HG. Role of IL-6, IL-2, and IL-4 in the in vitro induction of cytotoxic T cells. J Immunol 149:3316–3320, 1992.PubMedGoogle Scholar
  37. 37.
    Shabo Y, Lotem J, Rubinstein M, Revel M, Clark SC, Wolf SF, Kamen R, Sachs L. The myeloid blood cell differentiation-inducing protein MGI-2A is interleukin-6. Blood 72: 2070–2073, 1988.PubMedGoogle Scholar
  38. 38.
    Aderka D, Le JM, Vilcek J. IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J Immunol 143:3517–3523, 1989.PubMedGoogle Scholar
  39. 39.
    Bermudez LE, Wu M, Petrofsky M, Young LS. Interleukin-6 antagonizes tumor necrosis factor-mediated mycobacteriostatic and mycobactericidal activities in macrophages. Infect Immun 60:4245–4252, 1992.PubMedGoogle Scholar
  40. 40.
    Lacraz S, Nicod L, Galve-de Rochemonteix B, Baumberger C, Dayer JM, Welgus HG. Suppression of metalloproteinase biosynthesis in human alveolar macrophages by inter-leukin-4. J Clin Invest 90:382–388, 1992.PubMedCrossRefGoogle Scholar
  41. 41.
    Afford SC, Pongracz J, Stockley RA, Crocker J, Burnett D. The induction by human interleukin-6 of apoptosis in the promonocytic cell line U937 and human neutrophils. J Biol Chem 267:21612–21616, 1992.PubMedGoogle Scholar
  42. 42.
    Gauldie J, Richards C, Baumann H. IL6 and the acute phase reaction. Res Immunol 143:755–759, 1992.PubMedCrossRefGoogle Scholar
  43. 43.
    Kordula T, Guttgemann I, Rose-John S, Roeb E, Osthues A, Tschesche H, Koj A, Heinrich PC, Graeve L. Synthesis of tissue inhibitor of metalloproteinase-1 (TIMP-1) in human hepatoma cells (HepG2): Up-regulation by interleukin-6 and transforming growth factor beta 1. FEBS Lett 313:143–147, 1992PubMedCrossRefGoogle Scholar
  44. 44.
    Symington FW, Symington BE, Liu PY, Viguet H, Santhanam U, Sehgal PB. The relationship of serum IL-6 levels to acute graft-versus-host disease and hepatorenal disease after human bone marrow transplantation. Transplantation 54:457–462, 1992.PubMedCrossRefGoogle Scholar
  45. 45.
    Richards CD, Brown TJ, Shoyab M, Baumann H, Gauldie J. Recombinant oncostatin M stimulates the production of acute phase proteins in HepG2 cells and rat primary hepatocytes in vitro. J Immunol 148:1731–1736, 1992.PubMedGoogle Scholar
  46. 46.
    Zuraw BL, Lotz M. Regulation of the hepatic synthesis of C1 inhibitor by the hepatocyte stimulating factors interleukin 6 and interferon gamma. J Biol Chem 265:12664–12670, 1990.PubMedGoogle Scholar
  47. 47.
    Baumann H, Won KA, Jahreis GP. Human hepatocyte-stimulating factor-Ill and interleukin-6 are structurally and immunologically distinct but regulate the production of the same acute phase plasma proteins. J Biol Chem 264:8046–8051, 1989.PubMedGoogle Scholar
  48. 48.
    Geiger T, Andus T, Klapproth J, Hirano T, Kishimoto T, Heinrich PC. Induction of rat acute-phase proteins by interleukin 6 in vivo. Eur J Immunol 18:717–721, 1988.PubMedCrossRefGoogle Scholar
  49. 49.
    Guba SC, Sartor CI, Gottschalk LR, Jing YH, Mulligan T, Emerson SG. Bone marrow stromal fibroblasts secrete interleukin-6 and granulocyte-macrophage colony-stimulating factor in the absence of inflammatory stimulation: Demonstration by serum-free bioassay, enzyme-linked immunosorbent assay, and reverse transcriptase polymerase chain reaction. Blood 80:1190–1198, 1992.PubMedGoogle Scholar
  50. 50.
    Ogawa M. IL6 and haematopoietic stem cells. Res Immunol 143:749–751, 1992.PubMedCrossRefGoogle Scholar
  51. 51.
    Ikebuchi K, Wong GG, Clark SC, Ihle JN, Hirai Y, Ogawa M. Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors. Proc Natl Acad Sci USA 84:9035–9039, 1987.PubMedCrossRefGoogle Scholar
  52. 52.
    Patchen ML, MacVittie TJ, Williams JL, Schwartz GN, Souza LM. Administration of interleukin-6 stimulates multilineage hematopoiesis and accelerates recovery from radiation-induced hematopoietic depression. Blood 77:472–480, 1991.PubMedGoogle Scholar
  53. 53.
    Okano A, Suzuki C, Takatsuki F, Akiyama Y, Koike K, Nakahata T, Hirano T, Kishimoto T, Ozawa K, Asano S. Effects of interleukin-6 on hematopoiesis in bone marrow-transplanted mice. Transplantation, 1993.Google Scholar
  54. 54.
    Asano S, Okano A, Ozawa K, Nakahata T, Ishibashi T, Koike K, Kimura H, Tanioka Y, Shibuya A, Hirano T. In vivo effects of recombinant human interleukin-6 in primates: Stimulated production of platelets. Blood 75:1602–1605, 1990.PubMedGoogle Scholar
  55. 55.
    Ishibashi T, Kimura H, Shikama Y, Uchida T, Kariyone S, Hirano T, Kishimoto T, Takatsuki F, Akiyama Y. Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood 74:1241–1244, 1989.PubMedGoogle Scholar
  56. 56.
    Tanaka R, Koike K, Imai T, Shiohara M, Kubo T, Amano Y, Komiyama A, Nakahata T. Stem cell factor enhanes proliferation, but not maturation, of murine megakaryocytic progenitors in serum-free culture. Blood 80:1743–1749, 1992.PubMedGoogle Scholar
  57. 57.
    Brugger W, Mocklin W, Heimfeld S, Berenson RJ, Mertelsmann R, Kanz L. Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor, interleukin-1 beta (IL-1 beta), IL-6, IL-3, interferon-gamma, and erythropoietin. Blood 81:2579–2584, 1993.PubMedGoogle Scholar
  58. 58.
    Frei K, Malipiero UV, Leist TP, Zinkernagel RM, Schwab ME, Fontana A. On the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases. Eur J Immunol 19:689–694, 1989.PubMedCrossRefGoogle Scholar
  59. 59.
    Satoh T, Nakamura S, Taga T, Matsuda T, Hirano T, Kishimoto T, Kaziro Y. Induction of neuronal differentiation in PC12 cells by B-cell stimulatory factor 2/interleukin 6. Mol Cell Biol 8:3546–3549, 1988.PubMedGoogle Scholar
  60. 60.
    Kushima Y, Hatanaka H. Interleukin-6 and leukemia inhibitory factor promote the survival of acetylcholinesterase-positive neurons in culture from embryonic rat spinal cord. Neurosci Lett 143:110–114, 1992,PubMedCrossRefGoogle Scholar
  61. 61.
    Ip NY, Nye SH, Boulton TG, Davis S, Taga T, Li Y, Birren SJ, Yasukawa K, Kishimoto T, Anderson DJ. CNTF and LIF act on neuronal cells via shared signaling pathways that involve the IL-6 signal transducing receptor component gpl30. Cell 69:1121–1132, 1992.PubMedCrossRefGoogle Scholar
  62. 62.
    Toulmond S, Vige X, Fage D, Benavides J. Local infusion of interleukin-6 attentuates the neurotoxic effects of NMDA on rat striatal cholinergic neurons. Neurosci Lett 144:49–52, 1992.PubMedCrossRefGoogle Scholar
  63. 63.
    Dinarello CA, Cannon JG, Mancilla J, Bishai I, Lees J, Coceani F. Interleukin-6 as an endogenous pyrogen: Induction of prostaglandin E2 in brain but not in peripheral blood mononuclear cells. Brain Res 562:199–206, 1991.PubMedCrossRefGoogle Scholar
  64. 64.
    Woloski BM, Smith EM, Meyer WJ, Fuller GM, Blalock JE. Corticotropin-releasing activity of monokines. Science 230:1035–1037, 1985.PubMedCrossRefGoogle Scholar
  65. 65.
    Ohsaki Y, Takahashi S, Scarcez T, Demulder A, Nishihara T, Williams R, Roodman GD. Evidence for an autocrine/paracrine role for interleukin-6 in bone resorption by giant cells from giant cell tumors of bone. Endocrinology 131:2229–2234, 1992.PubMedCrossRefGoogle Scholar
  66. 66.
    Tamura T, Udagawa N, Takahashi N, Miyaura C, Tanaka S, Yamada Y, Koishihara Y, Ohsugi Y, Kumaki K, Taga T, et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sei USA 90:11924–11928, 1993.CrossRefGoogle Scholar
  67. 67.
    Ishimi Y, Miyaura C, Jin CH, Akatsu T, Abe E, Nakamura Y, Yamaguchi A, Yoshiki S, Matsuda T, Hirano T. IL-6 is produced by osteoblasts and induces bone resorption. J Immunol 145:3297–3303, 1990.PubMedGoogle Scholar
  68. 68.
    Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332:83–85, 1988.PubMedCrossRefGoogle Scholar
  69. 69.
    Jilka RL, Hangoc G, Girasole G, Passeri G, Williams DC, Abrams JS, Boyce B, Broxmeyer H, Manolagas SC. Increased osteoclast development after estrogen loss: Mediation by interleukin-6. Science 257:88–91, 1992.PubMedCrossRefGoogle Scholar
  70. 70.
    Kishimoto T, Akira S, Taga T. Interleukin-6 and its receptor: A paradigm for cytokines. Science 258:593–597, 1992.PubMedCrossRefGoogle Scholar
  71. 71.
    Crockard AD, Thompson JM, McBride SJ, Edgar JD, McNeill TA, Bell AL. Markers of inflammatory activation: Upregulation of complement receptors CR1 and CR3 on synovial fluid neutrophils from patients with inflammatory joint disease. Clin Immunol Immuno-pathol 65:135–142, 1992.CrossRefGoogle Scholar
  72. 72.
    Novick D, Engelmann H, Wallach D, Rubinstein M. Soluble cytokine receptors are present in normal human urine. J Exp Med 170:1409–1414, 1989.PubMedCrossRefGoogle Scholar
  73. 73.
    Yoshida K, Chambers I, Nichols J, Smith A, Saito M, Yasukawa K, Shoyab M, Taga T, Kishimoto T. Maintenance of the pluripotential phenotype of embryonic stem cells through direct activation of gpl30 signalling pathways. Mech Dev 45:163–171, 1994.PubMedCrossRefGoogle Scholar
  74. 74.
    Ward LD, Howlett GJ, Díscolo G, Yasukawa K, Hammacher A, Moritz RL, Simpson RJ. High affinity interleukin-6 receptor is a hexameric complex consisting of two molecules each of interleukin-6, interleukin-6 receptor, and gp-130. J Biol Chem 269:23286–23289, 1994.PubMedGoogle Scholar
  75. 75.
    Taga T, Narazaki M, Yasukawa K, Saito T, Miki D, Hamaguchi M, Davis S, Shoyab M, Yancopoulos GD, Kishimoto T. Functional inhibition of hematopoietic and neurotrophic cytokines by blocking the interleukin 6 signal transducer gpl30. Proc Natl Acad Sci USA 89:10998–11001, 1992.PubMedCrossRefGoogle Scholar
  76. 76.
    Nishimoto N, Ogata A, Shima Y, Tani Y, Ogawa H, Nakagawa M, Sugiyama H, Yoshizaki K, Kishimoto T. Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gpl30. J Exp Med 179:1343–1347, 1994.PubMedCrossRefGoogle Scholar
  77. 77.
    Zhang XG, Gu JJ, Lu ZY, Yasukawa K, Yancopoulos GD, Turner K, Shoyab M, Taga T, Kishimoto T, Bataille R, et al. Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gpl30. J Exp Med 179:1337–1342, 1994.CrossRefPubMedGoogle Scholar
  78. 78.
    Murakami M, Narazaki M, Hibi M, Yawata H, Yasukawa K, Hamaguchi M, Taga T, Kishimoto T. Critical cytoplasmic region of the interleukin 6 signal transducer gpl30 is conserved in the cytokine receptor family. Proc Natl Acad Sci USA 88:11349–11353, 1991.PubMedCrossRefGoogle Scholar
  79. 79.
    Nakajima K, Wall R. Interleukin-6 signals activating junB and TIS11 gene transcription in a B-cell hybridoma. Mol Cell Biol 11:1409–1418, 1991.PubMedGoogle Scholar
  80. 80.
    Narazaki M, Witthuhn BA, Yoshida K, Silvennoinen O, Yasukawa K, Ihle JN, Kishimoto T, Taga T. Activation of JAK2 kinase mediated by the interleukin 6 signal transducer gpl30. Proc Natl Acad Sei USA 91:2285–2289, 1994.CrossRefGoogle Scholar
  81. 81.
    Stahl N, Boulton TG, Farruggella T, Ip NY, Davis S, Witthuhn BA, Quelle FW, Silvennoinen O, Barbieri G, Pellegrini S, et al. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. Science 263:92–95, 1994.PubMedCrossRefGoogle Scholar
  82. 82.
    Boulton TG, Stahl N, Yancopoulos GD. Ciliary neurotrophic factor/leukemia inhibitory factor/interleukin 6/oncostatin M family of cytokines induces tyrosine phosphorylation of a common set of proteins overlapping those induced by other cytokines and growth factors. J Biol Chem 269:11648–11655, 1994.PubMedGoogle Scholar
  83. 83.
    Berger LC, Hawley TS, Lust JA, Goldman SJ, Hawley RG. Tyrosine phosphorylation of JAK-TYK kinases in malignant plasma cell lines growth-stimulated by interleukins 6 and 11. Biochem Biophys Res Commun 202:596–605, 1994.PubMedCrossRefGoogle Scholar
  84. 84.
    Lutticken C, Wegenka UM, Yuan J, Buschmann J, Schindler C, Ziemiecki A, Harpur AG, Wilks AF, Yasukawa K, Taga T, et al. Association of transcription factor APRF and protein kinase Jakl with the interleukin-6 signal transducer gp130. Science 263:89–92, 1994.PubMedCrossRefGoogle Scholar
  85. 85.
    Wegenka UM, Lutticken C, Buschmann J, Yuan J, Lottspeich F, Muller-Esterl W, Schindler C, Roeb E, Heinrich PC, Horn F. The interleukin-6-activated acute-phase response factor is antigenically and functionally related to members of the signal transducer and activator of transcription (STAT) family. Mol Cell Biol 14:3186–3196, 1994.PubMedGoogle Scholar
  86. 86.
    Akira S, Nishio Y, Inoue M, Wang XJ, Wei S, Matsusaka T, Yoshida K, Sudo T, Naruto M, Kishimoto T. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 77:63–71, 1994.PubMedCrossRefGoogle Scholar
  87. 87.
    Suematsu S, Matsuda T, Aozasa K, Akira S, Nakano N, Ohno S, Miyazaki J, Yamamura K, Hirano T, Kishimoto T. IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc Natl Acad Sci USA 86:7547–7551, 1989.PubMedCrossRefGoogle Scholar
  88. 88.
    Woodroofe C, Muller W, Ruther U. Long-term consequences of interleukin-6 over-expression in transgenic mice. DNA Cell Biol 11:587–592, 1992.PubMedCrossRefGoogle Scholar
  89. 89.
    Fattori E, Delia Rocca C, Costa P, Giorgio M, Dente B, Pozzi L, Ciliberto G. Development of progressive kidney damage and myeloma kidney in interleukin-6 transgenic mice. Blood 83:2570–2579, 1994.PubMedGoogle Scholar
  90. 90.
    Hawley RG, Fong AZ, Burns BF, Hawley TS. Transplantable myeloproliferative disease induced in mice by an interleukin 6 retrovirus. J Exp Med 176:1149–1163, 1992.PubMedCrossRefGoogle Scholar
  91. 91.
    Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, Zinkernagel R, Bluethmann H, Kohler G. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368:339–342, 1994.PubMedCrossRefGoogle Scholar
  92. 92.
    Revel M. Growth regulatory functions of IL6 and antitumour effects. Res Immunol 143:769–773, 1992.PubMedCrossRefGoogle Scholar
  93. 93.
    Brown TJ, Rowe JM, Liu JW, Shoyab M. Regulation of IL-6 expression by oncostatin M. J Immunol 147:2175–2180, 1991.PubMedGoogle Scholar
  94. 94.
    Givon T, Slavin S, Haran-Ghera N, Michalevicz R, Revel M. Antitumor effects of human recombinant interleukin-6 on acute myeloid leukemia in mice and in cell cultures. Blood 79:2392–2398, 1992.PubMedGoogle Scholar
  95. 95.
    Suzuki H, Yasukawa K, Saito T, Goitsuka R, Hasegawa A, Ohsugi Y, Taga T, Kishimoto T. Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo. Eur J Immunol 22:1989–1993, 1992.PubMedCrossRefGoogle Scholar
  96. 96.
    Westendorf JJ, Ahmann GJ, Armitage RJ, Spriggs MK, Lust JA, Greipp PR, Katzmann JA, Jelinek DF. CD40 expression in malignant plasma cells. Role in stimulation of autocrine IL-6 secretion by a human myeloma cell line. J Immunol 152:117–128, 1994.PubMedGoogle Scholar
  97. 97.
    Barut BA, Zon LI, Cochran MK, Paul SR, Chauhan D, Mohrbacher A, Fingeroth J, Anderson KC. Role of interleukin 6 in the growth of myeloma-derived cell lines. Leuk Res 16:951–959, 1992.PubMedCrossRefGoogle Scholar
  98. 98.
    Suematsu S, Matsusaka T, Matsuda T, Ohno S, Miyazaki J, Yamamura K, Hirano T, Kishimoto T. Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice. Proc Natl Acad Sci USA 89:232–235, 1992.PubMedCrossRefGoogle Scholar
  99. 99.
    Strassmann G, Fong M, Kenney JS, Jacob CO. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 89:1681–1684, 1992.PubMedCrossRefGoogle Scholar
  100. 100.
    Strassmann G, Fong M, Freter CE, Windsor S, D’Alessandro F, Nordan RP. Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo. J Clin Invest 92:2152–2159, 1993.PubMedCrossRefGoogle Scholar
  101. 101.
    Strassmann G, Fong M, Windsor S, Neta R. 1993. The role of interleukin-6 in lipopoly-saccharide-induced weight loss, hypoglycemia and fibrinogen production, in vivo. Cytokine 5:285–290, 1993.CrossRefGoogle Scholar
  102. 102.
    Libert C, Takahashi N, Cauwels A, Brouckaert P, Bluethmann H, Fiers W. Response of interleukin-6-deficient mice to tumor necrosis factor-induced metabolic changes and lethality. Eur J Immunol 24:2237–2242, 1994.PubMedCrossRefGoogle Scholar
  103. 103.
    Berek JS, Chung C, Kaldi K, Watson JM, Knox RM, Martinez-Maza O. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol 164:1038–42; discuss, 1991.PubMedGoogle Scholar
  104. 104.
    Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, Mercatello A, Ravault A, Tourani JM, Moskovtchenko JF. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 52:3317–3322, 1992.PubMedGoogle Scholar
  105. 105.
    Gastl G, Plante M, Finstad CL, Wong GY, Federici MG, Bander NH, Rubin SC. High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer. Br J Haematol 83:433–441, 1993.PubMedCrossRefGoogle Scholar
  106. 106.
    Plante M, Rubin SC, Wong GY, Federici MG, Finstad CL, Gastl GA. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer 73:1882–1888, 1994.PubMedCrossRefGoogle Scholar
  107. 107.
    Thaler J, Fechner F, Herold M, Huber H. Interleukin-6 in multiple myeloma: Correlation with disease activity and Ki-67 proliferation index. Leuk Lymphoma 12:265–271, 1994.PubMedCrossRefGoogle Scholar
  108. 108.
    Hirano T, Taga T, Yasukawa K, Nakajima K, Nakano N, Takatsuki F, Shimizu M, Murashima A, Tsunasawa S, Sakiyama F. Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production. Proc Natl Acad Sci USA 84:228–231, 1987.PubMedCrossRefGoogle Scholar
  109. 109.
    Guerne PA, Zuraw BL, Vaughan JH, Carson DA, Lotz M. Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis. J Clin Invest 83:585–592, 1989.PubMedCrossRefGoogle Scholar
  110. 110.
    Breviario F, d’Aniello EM, Golay J, Peri G, Bottazzi B, Bairoch A, Saccone S, Marzella R, Predazzi V, Rocchi M. Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component. J Biol Chem 267:22190–22197, 1992.PubMedGoogle Scholar
  111. 111.
    Finck BK, Chan B, Wofsy D. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J Clin Invest 94:585–591, 1994.PubMedCrossRefGoogle Scholar
  112. 112.
    Lotz M, Guerne PA. Interleukin-6 induces the synthesis of tissue inhibitor of metallopro-teinases-1/erythroid potentiating activity (TIMP-1/EPA). J Biol Chem 266:2017–2020, 1991.PubMedGoogle Scholar
  113. 113.
    Breen EC, Rezai AR, Nakajima K, Beall GN, Mitsuyasu RT, Hirano T, Kishimoto T, Martinez-Maza O. Infection with HIV is associated with elevated IL-6 levels and production. J Immunol 144:480–484, 1990.PubMedGoogle Scholar
  114. 114.
    Birx DL, Redfield RR, Tencer K, Fowler A, Burke DS, Tosato G. Induction of interleukin-6 during human immunodeficiency virus infection. Blood 76:2303–2310, 1990.PubMedGoogle Scholar
  115. 115.
    Martinez-Maza O. IL6 and AIDS. Res Immunol 143:764–769, 1992.Google Scholar
  116. 116.
    Oyaizu N, Chirmule N, Ohnishi Y, Kalyanaraman VS, Pahwa S. Human immunodeficiency virus type 1 envelope glycoproteins gpl20 and gpl60 induce interleukin-6 production in CD4+ T-cell clones. J Virol 65:6277–6282, 1991.PubMedGoogle Scholar
  117. 117.
    Amadori A, Zamarchi R, Veronese ML, Panozzo M, Barelli A, Borri A, Sironi M, Colotta F, Mantovani A, Chieco-Bianchi L. B cell activation during HIV-1 infection: II. Cell-to-cell interactions and cytokine requirement. J Immunol 146:57–62, 1991.Google Scholar
  118. 118.
    Poli G, Bressler P, Kinter A, Duh E, Timmer WC, Rabson A, Justement JS, Stanley S, Fauci AS. Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor alpha by transcriptional and post-transcriptional mechanisms. J Exp Med 172:151–158, 1990.PubMedCrossRefGoogle Scholar
  119. 119.
    Miles SA, Rezai AR, Salazar-Gonzalez JF, Vander Meyden M, Stevens RH, Logan DM, Mitsuyasu RT, Taga T, Hirano T, Kishimoto T. AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6. Proc Natl Acad Sci USA 87:4068–4072, 1990.PubMedCrossRefGoogle Scholar
  120. 120.
    Nair BC, DeVico AL, Nakamura S, Copeland TD, Chen Y, Patel A, O’Neil T, Oroszlan S, Gallo RC, Sarngadharan MG. Identification of a major growth factor for AIDS-Kaposi’s sarcoma cells as oncostatin M. Science 255:1430–1432, 1992.PubMedCrossRefGoogle Scholar
  121. 121.
    Miles SA, Martinez-Maza O, Rezai A, Magpantay L, Kishimoto T, Nakamura S, Radka SF, Linsley PS. Oncostatin M as a potent mitogen for AIDS-Kaposi’s sarcoma-derived cells. Science 255:1432–1434, 1992.PubMedCrossRefGoogle Scholar
  122. 122.
    Damas P, Ledoux D, Nys M, Vrindts Y, De Groote D, Franchimont P, Lamy M. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 215:356–362, 1992.PubMedCrossRefGoogle Scholar
  123. 123.
    Hack CE, De Groot ER, Felt-Bersma RJ, Nuijens JH, Strack RJ, Van Schijndel AJ, Eerenberg-Belmer L, Thijs G, Aarden LA. Increased plasma levels of interleukin-6 in sepsis (see comments). Blood 74:1704–1710, 1989.PubMedGoogle Scholar
  124. 124.
    Libert C, Vink A, Coulie P, Brouckaert P, Everaerdt B, Van Snick J, Fiers W. Limited involvement of interleukin-6 in the pathogenesis of lethal septic shock as revealed by the effect of monoclonal antibodies against interleukin-6 or its receptor in various murine models. Eur J Immunol 22:2625–2630, 1992.PubMedCrossRefGoogle Scholar
  125. 125.
    Weber JJ, Yang C, Topalian SL, Parkinson DR, Schwartzentruber DS, Ettinghausen SE, Gunn H, Mixon A, Kim H, Cole D, et al. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J Clin Oncol 11:499–506, 1993.PubMedGoogle Scholar
  126. 126.
    Mule JJ, Marcus SG, Yang JC, Weber JS, Rosenberg SA. Clinical application of IL6 in cancer therapy. Res Immunol 143:777–779, 1992.PubMedCrossRefGoogle Scholar
  127. 127.
    Marcus SG, Perry-Lalley D, Mule JJ, Rosenberg SA, Yang JC. The use of interleukin-6 to generate tumor-infiltrating lymphocytes with enhanced in vivo antitumor activity. J Immunother Emphasis Tumor Immunol 15:105–112, 1994.PubMedGoogle Scholar
  128. 128.
    Mullen CA, Coale MM, Levy AT, Stetler-Stevenson WG, Liotta LA, Brandt S, Blaese RM. Fibrosarcoma cells transduced with the IL-6 gene exhibited reduced tumorigenicity, increased immunogenicity, and decreased metastatic potential. Cancer Res 52:6020–6024, 1992.PubMedGoogle Scholar
  129. 129.
    Porgador A, Tzehoval E, Katz A, Vadai E, Revel M, Feldman M, Eisenbach L. Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res 52:3679–3686, 1992.PubMedGoogle Scholar
  130. 130.
    Patchen ML, Fischer R, MacVittie TJ. Effects of combined administration of interleukin-6 and granulocyte colony-stimulating factor on recovery from radiation-induced hemopoietic aplasia. Exp Hematol 21:338–344, 1993.PubMedGoogle Scholar
  131. 131.
    Mastorakos G, Chrousos GP, Weber JS. Recombinant interleukin-6 activates the hypo-thalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab 77:1690–1694, 1993.PubMedCrossRefGoogle Scholar
  132. 132.
    Swaak AJ, Lienard D, Schraffordt Koops H, Lejeune FJ, Eggermont AM. Effects of recombinant tumour necrosis factor (rTNF-alpha) in cancer: Observations on the acute phase protein reaction and immunoglobulin synthesis after high dose recombinant TNF-alpha administration in isolated limb perfusions in cancer patients. Eur J Clin Invest 23:812–818, 1993.PubMedCrossRefGoogle Scholar
  133. 133.
    Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW. Interleukin-6 (IL-6) as an antiinflammatory cytokine: Induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor reeptor p 55. Blood 83:113–118, 1994.PubMedGoogle Scholar
  134. 134.
    May LT, Patel K, Garcia D, Ndubuisi MI, Ferrone S, Mittelman A, Mackiewicz A, Sehgal PB. Sustained high levels of circulating chaperoned interleukin-6 after active specific cancer immunotherapy. Blood 84:1887–1895, 1994.PubMedGoogle Scholar
  135. 135.
    van Gameren MM, Willemse PH, Mulder NH, Limburg PC, Groen HJ, Vellenga E, deVries EG. Effects of recombinant human interleukin-6 in cancer patients: A phase I–II study. Blood 84:1434–1441, 1994.PubMedGoogle Scholar
  136. 136.
    Weber J, Gunn H, Yang J, Parkinson D, Topalian S, Schwartzentruber D, Ettinghausen S, Levitt D, Rosenberg SA. A phase I trial of intravenous interleukin-6 in patients with advanced cancer. J Immunother Emphasis Tumor Immunol 15:292–302, 1994.PubMedGoogle Scholar
  137. 137.
    Scheid C, Young R, McDermott R, Fitzsimmons L, Scarffe JH, Stern PL. Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase I clinical study: Induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity. Cancer Immunol Immunother 38:119–126, 1994.PubMedGoogle Scholar
  138. 138.
    Klein B, Wijdenes J, Zhang XG, Jourdan M, Boiron JM, Brochier J, Liautard J, Merlin M, Clement C, Morel-Fournier B. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 78:1198–1204, 1991.PubMedGoogle Scholar
  139. 139.
    Kreitman RJ, Siegall CB, FitzGerald DJ, Epstein J, Barlogie B, Pastan I. Interleukin-6 fused to a mutant form of Pseudomonas exotoxin kills malignant cells from patients with multiple myeloma. Blood 79:1775–1780, 1992.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1995

Authors and Affiliations

  • Martin Lotz

There are no affiliations available

Personalised recommendations